Physician profile
John Lee
NPI 1265499917
$9,303.84
in general payments reported to CMS, 2019-2025
39 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,903 · 2020: $703 · 2021: $1,359 · 2022: $1,926 · 2023: $1,374 · 2024: $973 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,503.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,466.78 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $1,279.79 | 2019-2025 | |
| Novo Nordisk INC | $914.05 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $815.94 | 2019-2024 | Repatha, Prolia, Evenity |
| Lilly USA, LLC | $739.89 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boston Scientific Corporation | $354.09 | 2022 | |
| Janssen Pharmaceuticals, INC | $338.19 | 2019-2022 | |
| Abbott Laboratories | $291.64 | 2021-2025 | Proclaim, Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $265.22 | 2019 | |
| Glaxosmithkline, LLC. | $248.73 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $164.01 | 2019-2024 | Gardasil 9, Gardasil, M-M-R II |
| E.R. Squibb & Sons, L.L.C. | $110.99 | 2019-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $99.12 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $74.46 | 2020-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.